A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Public ClinicalTrials.gov record NCT06079879. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
Study identification
- NCT ID
- NCT06079879
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 340 participants
Conditions and interventions
Conditions
Interventions
- Bomedemstat Drug
- Anagrelide Drug
- Busulfan Drug
- Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b Drug
- Ruxolitinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 30, 2023
- Primary completion
- Jul 29, 2027
- Completion
- Aug 17, 2028
- Last update posted
- Aug 12, 2026
2023 – 2028
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496) | Glendale | Arizona | 85304 | — |
| Los Angeles Cancer Network ( Site 3491) | Glendale | California | 91206 | — |
| Stanford Cancer Institute ( Site 0107) | Stanford | California | 94305-5826 | — |
| The Lundquist Institute ( Site 3423) | Torrance | California | 90502 | — |
| University of Colorado Anschutz Medical Campus ( Site 3425) | Aurora | Colorado | 80045 | — |
| Tufts Medical Center ( Site 3408) | Boston | Massachusetts | 02111 | — |
| University of Michigan ( Site 0008) | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Hospital ( Site 3413) | Detroit | Michigan | 48202 | — |
| Optum Care Cancer Center ( Site 3497) | Las Vegas | Nevada | 89102 | — |
| Roswell Park Cancer Institute ( Site 3421) | Buffalo | New York | 14263 | — |
| Duke University Health System (DUHS) ( Site 0016) | Durham | North Carolina | 27710 | — |
| Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400) | Winston-Salem | North Carolina | 27157 | — |
| Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8000) | Eugene | Oregon | 97401 | — |
| Medical University of South Carolina-Hollings Cancer Center ( Site 3426) | Charleston | South Carolina | 29425 | — |
| University of Virginia ( Site 3422) | Charlottesville | Virginia | 22908 | — |
| VCU Health Adult Outpatient Pavillion ( Site 3416) | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 147 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06079879, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 12, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06079879 live on ClinicalTrials.gov.